Healthcare Industry News: protein therapeutics
News Release - August 11, 2006
Altus Pharmaceuticals Appoints John M. Sorvillo, Ph.D. as Vice President of Business DevelopmentCAMBRIDGE, Mass.--(HSMN NewsFeed)--Aug. 11, 2006--Altus Pharmaceuticals Inc. (NASDAQ: ALTU ), a biopharmaceutical company developing and commercializing oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders, announced today that John M. Sorvillo, Ph.D. has been appointed Vice President of Business Development. In this position, Dr. Sorvillo will be responsible for establishing partnerships for Altus' late stage products and seeking development collaborations for its early stage and preclinical programs.
"We believe that John will be a tremendous asset to growing and expanding Altus' business," said Sheldon Berkle, President and CEO of Altus. "He has a proven track record in corporate development, deal making, and in- and out-licensing, and we are pleased that he brings this strong background to Altus."
Dr. Sorvillo has over 20 years of business and scientific experience in the biotechnology industry. Before joining Altus, Dr. Sorvillo was Chief Executive Officer of Bionaut Pharmaceuticals. Dr. Sorvillo also spent nine years as Vice President of Business Development at ArQule, where he was responsible for establishing corporate collaborations with pharmaceutical companies. While serving for 10 years at OSI Pharmaceuticals (formerly Oncogene Science), Dr. Sorvillo held a variety of positions leading up to his last position as Vice President and General Manager, Research Products Division. Dr. Sorvillo was a postdoctoral fellow at Memorial Sloan Kettering Cancer Center. He holds a Ph.D. in Immunology from the New York University Medical Center, Sackler Institute of Biomedical Sciences, and a B.A. in Biology from the City University of New York, Hunter College.
About Altus Pharmaceuticals Inc.:
Altus Pharmaceuticals, headquartered in Cambridge, MA is a biopharmaceutical company focused on the development and commercialization of oral and injectable protein therapeutics for patients with gastrointestinal and metabolic disorders. The Company's website is http://www.altus.com.
Source: Altus Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.